IsoRay (NYSEMKT:ISR) is rallying on Tuesday ahead of its participation in a major medical conference toward the end of the week. IsoRay, Inc. (NYSEMKT:ISR) shares after opening at $2.58 moved to $2.79 on last trade day and at the end of the day closed at $2.63. Company price to sales ratio in past twelve months was calculated as 30.86 and price to cash ratio as 32.27. IsoRay, Inc. (NYSEMKT:ISR) showed a positive weekly performance of 27.67%.
Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “neutral” rating restated by equities research analysts at MKM Partners in a research note issued to investors on Tuesday, Analyst RN reports. They currently have a $2.00 price target on the stock, up from their previous price target of $1.50. MKM Partners’ price objective suggests a potential upside of 10.50% from the company’s current price. Amarin Corporation plc (ADR) (NASDAQ:AMRN) shares advanced 6.08% in last trading session and ended the day on $1.92. AMRN return on equity ratio is recorded as 366.80% and its return on assets is -59.20%. Amarin Corporation plc (ADR) (NASDAQ:AMRN) yearly performance is -75.10%.
Arrowhead Research Corporation (NASDAQ:ARWR) announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. Arrowhead Research Corp (NASDAQ:ARWR) shares moved up 11.33% in last trading session and was closed at $18.28, while trading in range of $16.36 – $18.87. Arrowhead Research Corp (NASDAQ:ARWR) year to date (YTD) performance is 68.48%.
Research analysts at JMP Securities cut their target price on shares of Horizon Pharma Inc. (NASDAQ:HZNP) from $22.00 to $21.00 in a report released on Friday, ARN reports. Horizon Pharma Inc. (NASDAQ:HZNP) weekly performance is 6.85%. On last trading day company shares ended up $16.07. Horizon Pharma Inc. (NASDAQ:HZNP) distance from 50-day simple moving average (SMA50) is 34.71%. Analysts mean target price for the company is $20.80.